跳至主要内容
临床试验/NCT03278548
NCT03278548已完成4 期

Prospective, Randomized, Controlled, Double-blind, Multi-centre, Multinational Study on the Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery

Fresenius Kabi61 个研究点 分布在 9 个国家目标入组 2,289 人开始时间: 2017年9月28日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
2,289
试验地点
61
主要终点
Difference in mean estimated glomerular filtration rate (eGFR) (calculated from highest cystatin-C levels measured during post-operative days 1-3 (POD 1-3)) between the two treatment groups

研究概览

简要总结

The aim of the study is to investigate the safety of a 6% HES (Hydroxyethyl Starch) solution (Volulyte 6%) versus an electrolyte solution (Ionolyte) in patients undergoing elective abdominal surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
41 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Ionolyte

Active Comparator

Ionolyte solution for infusion

干预措施: Ionolyte (Drug)

Volulyte 6%

Experimental

Volulyte 6% solution for infusion

干预措施: Volulyte 6% (Drug)

结局指标

主要结局

Difference in mean estimated glomerular filtration rate (eGFR) (calculated from highest cystatin-C levels measured during post-operative days 1-3 (POD 1-3)) between the two treatment groups

时间窗: post-operative days 1-3

次要结局

  • Major post-operative complications(until post-operative day 90)
  • Mortality(1 year)
  • Composite of mortality and major post-operative complications (including renal)(until post-operative day 90)
  • Total volume of administered investigational product(until 24 hours after investigational product treatment start)
  • Fluid balance [Sum of volume of all intravenous medication (including investigational product and blood products) minus sum of volume of urine output (if available), drainage and estimated intra-operative blood loss](until post-operative day 3)
  • Heart Rate(until post-operative day 3)
  • Renal function(until 1 year after surgery)
  • Calculated red blood cell (RBC) loss(on post-operative day 3)
  • Inflammation(until post-operative day 1)
  • Estimated intra-operative blood loss(end of surgery)
  • Coagulation(until post-operative day 1)
  • Adverse events(until post-operative day 90)
  • Body temperature(until post-operative day 3)
  • Mean arterial pressure(until post-operative day 3, if available)
  • Systolic arterial blood pressure(until end of surgery)
  • Diastolic arterial blood pressure(until end of surgery)
  • Central venous pressure (if available)(until end of surgery)
  • Haemodynamics readings as required to determine volume responsiveness [at least one parameter (stroke volume, stroke volume variation, stroke volume index, pulse pressure variation, mean arterial pressure) has to be used to guide volume administration](until 24 hours after investigational product treatment start)
  • Partial pressure of carbon dioxide(until end of surgery)
  • Partial pressure of oxygen(until end of surgery)
  • Bicarbonate(until end of surgery)
  • Arterial oxygen saturation(until end of surgery)
  • Haemoglobin(until post-operative day 3)
  • Haematocrit(until post-operative day 3)
  • pH(until end of surgery)
  • Base Excess(until end of surgery)
  • Lactate(until post-operative day 3)
  • Central venous oxygen saturation (if available)(until post-operative day 1)
  • Serum sodium(until post-operative day 1)
  • Serum potassium(until post-operative day 1)
  • Serum calcium(until post-operative day 1)
  • Serum chloride(until post-operative day 1)
  • Length of stay in the hospital/intensive care unit(until post-operative day 90)
  • Hours on mechanical ventilation(until post-operative day 7)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (61)

Loading locations...

相似试验